Extensive preclinical investigations with GLP-1 and subsequent clinical investigations with the GLP-1R agonists and DPP-4 inhibitors in humans, including patients with T2DM, have been undertaken to determine the actions of each of these agents in regulating glucose. Here, GCG is linked to type 2 diabetes mellitus.